Group 1 - The company Tianjin Development (00882.HK) announced a financial agreement involving its indirect non-wholly owned subsidiary, Lifescience Pharmaceuticals [1] - The agreement is with Bohai Bank for a structured deposit with a principal amount of RMB 210 million, equivalent to approximately HKD 230 million [1]

Group 1 - The company Tianjin Development (00882) announced a financial agreement involving its indirect non-wholly owned subsidiary, Lifesun Pharmaceutical (002393) [1] - Lifesun Pharmaceutical entered into a structured deposit agreement with Bohai Bank, with a principal amount of RMB 210 million [1]

Group 1 - The company Tianjin Development (00882) announced a financial agreement involving its indirect non-wholly owned subsidiary, Lisheng Pharmaceutical, with Bohai Bank [1] - The agreement includes a structured deposit with a principal amount of RMB 210 million [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 由於根據上市規則第 14.07 條計算有關認購事項之本金金額的其中一項適用 百分比率超過 5%但全部均低於 25%，認購事項構成本公司的須予披露交易， 並須遵守上市規則第 14 章項下的申報及公告規定。 渤海銀行理財協議 於二零二五年十一月十一日，力生製藥與渤海銀行訂立渤海銀行理財協議，以 本金金額人民幣 210,000,000 元（相當於約港幣 229,759,300 元）認購一筆結構 性存款。 須予披露交易 認購理財產品 渤海銀行理財協議 於二零二五年十一月十一日，力生製藥（本公司間接非全資附屬公司）與渤 海銀行訂立渤海銀行理財協議，以本金金額人民幣 210,000,000 元（相當於約 港幣 229,759,300 元）認購一筆結構性存款。 上市規則涵義 （於香港註冊成立之有限公司） （股份代號： 882 ） 認購事項的存款期限為自二零二五年十一月十三日起至二零二六年十一月十三 日止（包括首尾兩日 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年10月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 天津發展控股有限公司 呈交日期: 2025年11月3日 I. 法定/註冊股本變動 不適用 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 00882 | 說明 | | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | | 1,072,770,125 | | 0 | | 1,072,770,125 | | 增加 / 減少 (-) | | | | | | | | | | 本月底結存 | | | | 1,072,770,125 | | 0 ...

Core Viewpoint - Tianjin Development (00882.HK) announced that Lifesun Pharmaceutical (002393.SZ) achieved a revenue of 1.007 billion yuan in the first three quarters of 2025, reflecting a year-on-year decrease of 1.61% while net profit attributable to shareholders increased by 119.05% to 370 million yuan [1] Financial Performance - Lifesun Pharmaceutical's revenue for the first three quarters of 2025 was 1.007 billion yuan, down 1.61% year-on-year [1] - The net profit attributable to shareholders reached 370 million yuan, showing a significant increase of 119.05% compared to the previous year [1] - The net profit excluding non-recurring gains and losses was 127 million yuan, which represents a year-on-year growth of 19.21% [1] - Basic earnings per share were reported at 1.44 yuan [1]

Core Viewpoint - Tianjin Development (00882) reported a mixed financial performance for its indirect non-wholly owned subsidiary, Tianjin Lisheng Pharmaceutical Co., Ltd., with a slight decline in revenue but a significant increase in net profit [1] Financial Performance - Total revenue for the nine months ending September 30, 2025, was 1.007 billion yuan, representing a year-on-year decrease of 1.61% [1] - Net profit attributable to the parent company's owners was 371 million yuan, showing a year-on-year increase of 119.05% [1] - Basic earnings per share stood at 1.44 yuan [1]

力生製藥乃一間於中華人民共和國成立的公司，其股份於深圳證券交易所上市。 於本公告日期，本公司間接持有力生製藥約34.11%之已發行股本。根據中國企 業會計準則而編制之力生製藥截至二零二五年九月三十日止九個月之未經審核 合併利潤表及於二零二五年九月三十日之未經審核簡明合併資產負債表載列如 下： - 1 - 天津力生製藥股份有限公司 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對 其準確性或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份 內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （於香港註冊成立之有限公司） （股份代號：882） 天津力生製藥股份有限公司 截至二零二五年九月三十日止九個月之 未經審核財務業績 本公告乃天津發展控股有限公司（「本公司」）根據證券及期貨條例（香港法 例第571章）第XIVA部及香港聯合交易所有限公司證券上市規則第13.09條而作 出，向本公司股東及公眾人士提供其間接非全資附屬公司天津力生製藥股份有 限公司（「力生製藥」）截至二零二五年九月三十日止九個月之未經審核合併 財務業績。 - 3 - 合併利潤表 截至二零二五年九月三十 ...

(Incorporated in Hong Kong with limited liability) （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） (Stock Code 股 份 代 號 : 882) NOTIFICATION LETTER 通知信函 17 October 2025 Dear Non-registered Shareholder(s) (Note 1), Notification of Publication of Circular and Notice of Extraordinary General Meeting (the "Current Corporate Communication") We are pleased to inform you that the Current Corporate Communication of Tianjin Development Holdings Limited (the "Company"), in English and Chinese, is now available on the Company's website at ...

(Incorporated in Hong Kong with limited liability) （ 於 香 港 註 冊 成 立 之 有 限 公 司 ） (Stock Code 股 份 代 號 : 882) NOTIFICATION LETTER 通知信函 17 October 2025 敬啟者： 通函、股東特別大會通告及代表委任表格 （「本次公司通訊」）的刊發通知 Dear Shareholders, Notification of Publication of Circular, Notice of Extraordinary General Meeting and Form of Proxy (the "Current Corporate Communication") We are pleased to inform you that the Current Corporate Communication of Tianjin Development Holdings Limited (the "Company"), in English and Chinese, is now available ...